Obexelimab reduces IgG4-related disease flares

Weekly obexelimab reduced disease flares and steroid rescue use in active immunoglobulin G4-related disease.
*Randomized controlled trial; Level 2 (OCEBM).

Citation

Della-Torre E, Baker MC, Zhang W, et al. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med. 2026;395:1273-1284. doi:10.1056/NEJMoa2601337

Background

Immunoglobulin G4-related disease is a chronic inflammatory condition that can damage many organs. Steroids often work initially, but relapse and steroid side effects are common, creating a need for safer long-term control.

Patients

194 adults with active immunoglobulin G4-related disease involving at least one organ. Key exclusions included active infection, recent high-dose steroids, and recent B-cell–depleting or other immune-modifying therapy.

Intervention

Obexelimab 250 mg injected under the skin once weekly for 52 weeks, with standardized steroid taper to discontinuation by week 8.

Control

Matching placebo injections, with the same steroid induction and taper.

Outcome

Primary: time to first disease flare needing rescue therapy. Secondary: complete remission, steroid rescue dose, and steroid toxicity using the Glucocorticoid Toxicity Index (0 to 410; higher is worse).

Follow-up Period

52 weeks.

Results

Outcome Obexelimab Placebo Effect
First flare needing rescue therapy (primary) 26.8% 54.6% Hazard ratio 0.44 (95% CI 0.28 to 0.71); NNT 4
Complete remission at week 52 37.1% 19.6% Risk difference 17.7 points (95% CI 5.4 to 30.0); NNT 6
Cumulative rescue steroid dose 329.5 mg 929.8 mg Mean difference −600.3 mg (95% CI −1011.1 to −189.5)

Analyses were intention-to-treat. This was not a non-inferiority trial. The steroid toxicity difference was 11.4 points (95% CI 1.7 to 21.1), below the stated 15-point minimally important difference. The control was not an active biologic comparator. Serious adverse events occurred in 10.3% versus 18.6%; statistical significance was not reported.

Limitations

Follow-up was only 52 weeks for a chronic relapsing disease. Long-term safety, durability, and cost remain uncertain. Sponsor involvement and medical writing support may introduce bias. Racial and regional imbalances may limit generalizability.

Funding

Zenas BioPharma; sponsor involvement raises potential bias.

Clinical Application

For active immunoglobulin G4-related disease, consider obexelimab as a steroid-sparing option, pending long-term safety and comparison with approved biologic therapy.